Last reviewed · How we verify
A Long-term Follow-up Study of GF-01-01 to Evaluate the Safety and Persistence of GF-CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
The goal of this observational study is to learn about the long-term safety of GF-CART01 after cell infusion up to 15 years.
Details
| Lead sponsor | GenomeFrontier Therapeutics TW Co., Ltd. |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 18 |
| Start date | 2026-05 |
| Completion | 2041-05 |
Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma (FL)
- Primary Mediastinal Large B-Cell Lymphoma
- High Grade B Cell Lymphoma
Primary outcomes
- Long-Term Safety of GF-CART01 after infusion — up to 15 years after GF-CART01 infusion
Percentage of subjects with ≥ grade 3 GF-CART01-related adverse events, serious adverse events (SAEs), adverse events of special interest (AESIs)
Countries
Taiwan